RP 66364

Drug Profile

RP 66364

Latest Information Update: 17 Feb 1995

Price : $50

At a glance

  • Originator Aventis
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation; Rheumatic disorders

Most Recent Events

  • 17 Feb 1995 Discontinued-Preclinical for Rheumatic disorders in France (Unknown route)
  • 17 Feb 1995 Discontinued-Preclinical for Inflammation in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top